Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

• Main Authors: Celeste M. Boesjes (Author), Esmé Kamphuis (Author), Nicolaas P.A. Zuithoff (Author), Daphne S. Bakker (Author), Laura Loman (Author), Lotte S. Spekhorst (Author), Inge Haeck (Author), Marijke Kamsteeg (Author), Anneke M.T. van Lynden-van Nes (Author), Floor M. Garritsen (Author), Klaziena Politiek (Author), Marja Oldhoff (Author), Marlies de Graaf (Author), Marie L.A. Schuttelaar (Author), Marjolein S. de Bruin-Weller (Author)
• Format: Book
• Published: Medical Journals Sweden, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentre prospective study evaluated the effectiveness and safety of 16-week...